Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Debuts US Azopt Rival

Brinzolamide 1% Ophthalmic Suspension Developed And Manufactured By Indoco

Executive Summary

Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.

You may also be interested in...



Indoco’s US Business Grows After Azopt Rival Launch

India’s Indoco saw its international business grow after Teva launched the Indoco-manufactured and developed first US generic version of Novartis’ Azopt (brinzolamide) 1% solution. Though the company saw muted domestic growth, it aims to bolster its overall performance by launching 20 products a year by 2023.

Teva Identifies ‘Problem Pattern’ Of Complex CRLs Ahead Of GDUFA III

Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.

Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021

Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel